En respuesta a la pandemia actual del COVID-19 (coronavirus), el equipo del estudio ANCHOR ha aconsejado al personal clínico local a que se comunique con los participantes del estudio que ya tienen cita programada durante las próximas 4 semanas para determinar si uno debe acudir a la clínica, o no. Si no recibes noticia del personal clínico de tu local, favor de contactarlos. Si estás en espera de la visita de evaluación, te agradecemos tu paciencia. Sí te atenderemos tan pronto como sea posible, una vez que sea seguro hacerlo. Mientras tanto, puedes comunicarte con tu clínica local del estudio ANCHOR si tienes alguna duda o inquietud.
Beliefs About Anal Cancer among HIV-Infected Women: Barriers and Motivators to Participation in Research
December 15, 2015
Infection with the human immunodeficiency virus (HIV) remains associated with a greater risk of anal cancer, despite widespread use of combination antiretroviral therapy. Evidence concerning the acceptability of anal cancer screening gives little attention to women. Because HIV-infected women have a high prevalence of depression and history of sexual trauma, understanding acceptability among this group is critical.
We sought to assess barriers and motivators to participation in anal cancer screening research among a racial/ethnically diverse HIV-infected female population.
We conducted a survey based on the Health Belief Model to identify characteristics of women willing to participate in anal cancer screening research (n = 200). Bivariate analyses examined associations between willingness to participate and sociodemographics, clinical characteristics, and health beliefs. Logistic regression modeled willingness to participate in research.
Of the women who participated, 37% screened positive for depression, 43% reported a high trauma history, and 36% screened positive for posttraumatic stress disorder. Overall, 65% reported willingness to participate in research. Those likely to participate were older, reported intravenous drug use as their HIV risk factor, and had a history of prior high-resolution anoscopy (HRA) compared with those unwilling to participate. The most commonly reported barrier to anal Pap testing was fear of pain. In adjusted analyses, a lack of fear of pain and prior experience with HRA significantly predicted willingness to participate.
Findings suggest that, to increase participation in anal Pap and HRA-related research for HIV-infected women, a single approach may not be adequate. Rather, we must harness patients' previous experiences and address psychosocial and financial concerns to overcome barriers to participation.